echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Metabolism: Prehospital use of hypoglycemic agents and mortality in patients with type 2 diabetes and COVID-19

    Metabolism: Prehospital use of hypoglycemic agents and mortality in patients with type 2 diabetes and COVID-19

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Since the end of 2019, SARS-CoV-2, as a newly emerged pathogenic microorganism, has caused the pandemic of new coronary pneumonia
    .


    As of the end of November 2021, more than 257 million people worldwide have been infected with SARS-CoV-2, of which about 5.


    New coronary pneumonia infection COVID-19 diabetes hypertensive blood vessels

    Recently, a research article was published in Metabolism-Clinical and Experimental, an authoritative journal in the field of metabolic diseases.
    The researchers aimed to compare the impact of pre-admission antidiabetic drugs on in-hospital mortality in patients with type 2 diabetes and COVID-19
    .

    We systematically searched PubMed, EMBASE, Scopus and Web of Science databases for studies (excluding case reports and review articles) published up to 30 November 2021
    .


    The researchers excluded papers on the use of antidiabetic drugs during hospitalization


    We included 61 studies (3,061,584 participants), which were rated as low risk of bias
    .


    OR (95% CI) indicated that some drugs against covid-19-related deaths, including metformin [0.


    metformin

    CONCLUSIONS : Metformin, GLP-1RA and SGLT-2i were associated with lower mortality in T2DM patients with COVID-19
    .


    DPP-4i and insulin are associated with increased mortality


    Metformin, GLP-1RA, and SGLT-2i were associated with lower mortality in patients with type 2 diabetes with COVID-19


    Original source:

    Nam Nhat Nguyen.


    Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta- analysis
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.